Download PDF
Int J Angiol 2019; 28(04): 262-266
DOI: 10.1055/s-0038-1661003
Case Report
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Treatment of Deep Vein Thrombosis in May–Thurner's Syndrome with a Novel Oral Anticoagulant: A Case Report

Toh Ching Han
1   Department of General Medicine, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore
,
Ashish Anil Sule
2   Department of General Medicine, Subspecialty of Vascular Medicine and Hypertension, Tan Tock Seng Hospital, Singapore, Singapore
› Author Affiliations
Further Information

Publication History

Publication Date:
20 June 2018 (online)

    Permissions and Reprints

Abstract

May–Thurner's syndrome (MTS) is an anatomical variant where the left common iliac vein (CIV) is compressed by the overlying right common iliac artery and the underlying lumbar vertebrae, leading to stenosis in the left CIV. Endovascular intervention followed by anticoagulation currently constitute the mainstay of management of MTS associated with recurrent deep vein thrombosis (DVT).

Warfarin appears to be the anticoagulant of choice in most studies conducted in patients with MTS. There is little evidence of treatment using nonvitamin K oral anticoagulants. This case report serves to describe a patient with MTS who was successfully treated with catheter-directed therapy followed by anticoagulation using rivaroxaban.

A 64-year-old women presented with left lower limb swelling. Her duplex ultrasound and computed tomography (CT) showed extensive DVT and underlying narrowing of the left CIV, respectively.

She underwent catheter-directed therapy, involving stent placement in the left CIV, and was subsequently started on rivaroxaban. She developed partial thrombosis of the external iliac vein at 5 months postprocedure and partial stent thrombosis at 1 year postprocedure while on rivaroxaban, requiring repeat stenting and continuation of anticoagulation. On follow-up, there was no recurrence of symptoms related to MTS, no postthrombotic syndrome, and no clinically significant bleeding as a side effect of rivaroxaban.

This case report shows that rivaroxaban is a safe agent that can be successfully used in the treatment of MTS after stenting.

Keywords

deep vein thrombosis - venous outflow - common iliac vein - anticoagulation - artery - DVT - endovascular therapy
 

  • References

  • 1 Birn J, Vedantham S. May-Thurner syndrome and other obstructive iliac vein lesions: meaning, myth, and mystery. Vasc Med 2015; 20 (01) 74-83
    CrossrefPubMedGoogle Scholar
  • 2 Mousa AY, AbuRahma AF. May-Thurner syndrome: update and review. Ann Vasc Surg 2013; 27 (07) 984-995
    CrossrefPubMedGoogle Scholar
  • 3 May R, Thurner J. The cause of the predominantly sinistral occurrence of thrombosis of the pelvic veins. Angiology 1957; 8 (05) 419-427
    CrossrefPubMedGoogle Scholar
  • 4 Wang C-N, Deng H-R. Percutaneous endovenous intervention plus anticoagulation versus anticoagulation alone for treating patients with proximal deep vein thrombosis: a meta-analysis and systematic review. Ann Vasc Surg 2018; 49: 39-48
    CrossrefPubMedGoogle Scholar
  • 5 Soosainathan A, Moore HM, Gohel MS, Davies AH. Scoring systems for the post-thrombotic syndrome. J Vasc Surg 2013; 57 (01) 254-261
    CrossrefPubMedGoogle Scholar
  • 6 Elsharawy M, Elzayat E. Early results of thrombolysis vs anticoagulation in iliofemoral venous thrombosis. A randomised clinical trial. Eur J Vasc Endovasc Surg 2002; 24 (03) 209-214
    CrossrefPubMedGoogle Scholar
  • 7 Enden T, Haig Y, Kløw NE. , et al; CaVenT Study Group. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet 2012; 379 (9810): 31-38
    CrossrefPubMedGoogle Scholar
  • 8 Peters M, Syed RK, Katz M. , et al. May-Thurner syndrome: a not so uncommon cause of a common condition. Proc Bayl Univ Med Cent 2012; 25 (03) 231-233
    CrossrefPubMedGoogle Scholar
  • 9 Meissner MH, Gloviczki P, Comerota AJ. , et al; Society for Vascular Surgery; American Venous Forum. Early thrombus removal strategies for acute deep venous thrombosis: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg 2012; 55 (05) 1449-1462
    CrossrefPubMedGoogle Scholar
  • 10 Kearon C, Akl EA, Ornelas J. , et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
    CrossrefPubMedGoogle Scholar
  • 11 Zhang X, Shi X, Gao P. , et al. Endovascular management of May-Thurner syndrome: a case report. Medicine (Baltimore) 2016; 95 (04) e2541
    PubMedGoogle Scholar
  • 12 Hager ES, Yuo T, Tahara R. , et al. Outcomes of endovascular intervention for May-Thurner syndrome. J Vasc Surg Venous Lymphat Disord 2013; 1 (03) 270-275
    CrossrefPubMedGoogle Scholar
  • 13 Igari K, Kudo T, Toyofuku T, Jibiki M, Inoue Y. Surgical thrombectomy and simultaneous stenting for deep venous thrombosis caused by iliac vein compression syndrome (May-Thurner syndrome). Ann Thorac Cardiovasc Surg 2014; 20 (06) 995-1000
    CrossrefPubMedGoogle Scholar
  • 14 Kim J-Y, Choi D, Guk Ko Y, Park S, Jang Y, Lee DY. Percutaneous treatment of deep vein thrombosis in May-Thurner syndrome. Cardiovasc Intervent Radiol 2006; 29 (04) 571-575
    CrossrefPubMedGoogle Scholar
  • 15 Chai-Adisaksopha C, Hillis C, Isayama T, Lim W, Iorio A, Crowther M. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost 2015; 13 (11) 2012-2020
    CrossrefPubMedGoogle Scholar